Stay updated on DC Therapy After Cryosurgery With Pembrolizumab in Melanoma Clinical Trial
Sign up to get notified when there's something new on the DC Therapy After Cryosurgery With Pembrolizumab in Melanoma Clinical Trial page.

Latest updates to the DC Therapy After Cryosurgery With Pembrolizumab in Melanoma Clinical Trial page
- Check4 days agoChange DetectedPage revision updated from v3.6.4 to v3.6.5, signaling a minor version update rather than changes to the study content.SummaryDifference0.0%

- Check11 days agoNo Change Detected
- Check18 days agoChange DetectedRevision: v3.6.4 was added (replacing v3.6.3), reflecting an administrative update to the page.SummaryDifference0.0%

- Check25 days agoNo Change Detected
- Check39 days agoChange DetectedThe page now displays revision v3.6.3, replacing the previous v3.6.2; this indicates a minor page version update to the study record.SummaryDifference0.0%

- Check47 days agoChange DetectedPage revision updated from v3.6.0 to v3.6.2, indicating a minor update to the ClinicalTrials.gov entry. The change reflects version control or backend adjustments rather than substantive changes to the study data or eligibility criteria.SummaryDifference0.0%

- Check61 days agoChange DetectedThe study record now shows 'No longer looking for participants', indicating termination due to poor accrual and no further enrollment. Additionally, the page adds navigation/help sections (How to Read a Study Record, Common Questions, How to Join a Study) and updates the revision stamp from v3.5.5 to v3.6.0.SummaryDifference0.5%

- Check68 days agoChange DetectedPage revision updated from v3.5.4 to v3.5.5, signaling a minor update to the page’s documentation. The core study details, eligibility criteria, and results information appear unchanged.SummaryDifference0.0%

Stay in the know with updates to DC Therapy After Cryosurgery With Pembrolizumab in Melanoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the DC Therapy After Cryosurgery With Pembrolizumab in Melanoma Clinical Trial page.